Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
Sun, 09/10/17 - 11:56 am
Tags:
AbbVie, JAK inhibitors, clinical trials, atopic dermatitis, Upadacitinib, Sanofi, Regeneron, Dupixent
This Shield of Patents Protects the World’s Best-Selling Drug
Bloomberg
Fri, 09/8/17 - 09:25 am
Tags:
patents, AbbVie, Humira
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
Endpoints
Thu, 09/7/17 - 09:46 am
Tags:
AbbVie, ABT-494, atopic dermatitis, Upadacitinib
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
Thu, 08/31/17 - 09:27 am
Tags:
hepatitis C, Gilead Sciences, Merck, AbbVie, Bristol-Myers Squibb
Pharma Stocks That Could Move On New Data
Barron's
Sat, 08/26/17 - 07:36 pm
Tags:
pharma stocks, AbbVie, Bayer, Novartis, Bristol-Myers Squibb, Eli Lilly, European Society of Cardiology
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Fri, 08/25/17 - 09:52 am
Tags:
Biogen, Samsung Bioepis, Europe, Humira, AbbVie, Imraldi, biosimilars
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
Thu, 08/17/17 - 10:36 am
Tags:
patents, AbbVie, Humira, Pfizer, Lipitor, Norvasc, GSK, Advair, Sanofi, Lantus, JNJ, Remicade, AstraZeneca, Crestor, Nexium, Amgen, Neulasta, Novartis, Diovan
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
Thu, 08/10/17 - 06:58 pm
Tags:
pharma stocks, Merck, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, GSK, Roche, Sanofi, Bayer, Novo Nordisk, Celgene, Biogen, AstraZeneca
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
Sun, 08/6/17 - 09:48 pm
Tags:
AbbVie, hepatitis C, Mavyret, Gilead Sciences, Merck
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
Sat, 08/5/17 - 09:44 am
Tags:
AbbVie, Gilead Sciences, hepatitis C, Mavyret
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
Fri, 08/4/17 - 11:32 am
Tags:
AbbVie, hepatitis C, Mavyret, drug pricing
J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval
Fierce Pharma
Wed, 08/2/17 - 09:33 pm
Tags:
JNJ, AbbVie, Imbruvica, graft vs host disease, FDA
AbbVie confident in strategy as Humira mints money
BioPharma Dive
Sat, 07/29/17 - 09:44 am
Tags:
AbbVie, Humira
AbbVie scores surprisingly good Q2 results but pipeline worries persist
Fierce Pharma
Fri, 07/28/17 - 10:42 pm
Tags:
AbbVie, earnings
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Motley Fool
Thu, 07/27/17 - 09:47 am
Tags:
Gilead Sciences, AbbVie, hepatitis C, reorganization
Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart
Endpoints
Wed, 07/26/17 - 09:49 am
Tags:
Eli Lilly, JNJ, AbbVie, WuXi, regenerative medicine, Rodeo Therapeutics
AbbVie Ordered to Pay $150 Million Damages in ‘Low-T’ Trial
Bloomberg
Tue, 07/25/17 - 12:04 am
Tags:
AbbVie, Androgel, low testosterone, blood clots
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Sun, 07/23/17 - 11:47 am
Tags:
Biogen, aducanumab, JNJ, apalutamide, Eli Lilly, abemaciclib, AbbVie, Rova-T, Celgene, ozanimod
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
Wed, 07/19/17 - 07:55 pm
Tags:
AbbVie, Gilead Sciences, hepatitis C, Vosevi, Harvoni, Sovaldi, Epclusa, Viekira Pak
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Tue, 07/18/17 - 11:32 am
Tags:
Big Pharma, Roche, AstraZeneca, AbbVie, Gilead Sciences, JNJ

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.